NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up
No signs or symptoms of overexpression toxicity, including in one patient with a mild.
Neurogene (NASDAQ:NGNE – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $55.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 50.15% from the company’s previous close. Several other analysts also […]
Neurogene (NASDAQ:NGNE) Receives New Coverage from Analysts at SVB Leerink themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
SVB Leerink started coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note published on Monday, Marketbeat reports. The firm issued an outperform rating and a $46.00 price target on the stock. NGNE has been the subject of a number of other research reports. William Blair began coverage on Neurogene in a […]